Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dmaa · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) measures how much investors pay for each dollar of the company's trailing earnings. DMAA's current PE ratio of 36.69x is calculated by dividing its stock price of $10.62 by its TTM earnings per share of $0.29. +0.1% elevated vs 5Y avg 36.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2024 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Shell Companies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Drugs Made In America Acquisition Corp. Ordinary SharesYou DMAA | $358M | 36.69x | -0.1% | $0.29 |
 Centurion Acquisition Corp. ALF | $391M | 32.59x | -11.2% | $0.33 |
 Live Oak Acquisition Corp. V Class A Ordinary Shares LOKV | $303M | N/A | — | -$0.86 |
 Mountain Lake Acquisition Corp. MLAC | $203M | 29.89x | -18.6% | $0.35 |
 Oyster Enterprises II Acquisition Corp OYSE | $348M | 27.65x | -24.7% | $0.37 |
 Renatus Tactical Acquisition Corp I Class A Ordinary Shares RTAC | $326M | 65.77x | +79.1% | $0.16 |
 SIM Acquisition Corp. I SIMA | $334M | 27.71x | -24.5% | $0.38 |
Industry Average 5 peers with valid PE | — | 36.72x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 36.67x | $0.28 | — | |
2024-12-31 FY2024 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) measures how much investors pay for each dollar of the company's trailing earnings. DMAA's current PE ratio of 36.69x is calculated by dividing its stock price of $10.62 by its TTM earnings per share of $0.29.
Frequently asked questions
DMAA pe ratio · 6 questionsDMAA's current PE ratio is 36.69x as of 2026-06-09, based on a stock price of $10.62 and TTM EPS of $0.29. Data sourced from Financial Modeling Prep via DMAA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Drugs Made In America Acquisition Corp. Ordinary Shares SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09